What is it about?

This review features emerging treatment options for cancer-associated cachexia including promising new agents, and multidrug as well as multimodal approaches tested in the past or on-going RCTs.

Featured Image

Why is it important?

There are two hurdles in conducting clinical trials in patients with cachexia. First, vulnerability of cachectic cancer patients leads to poor recruitment, retention, and compliance. Second, a lack of widely accepted endpoints impedes the research progress. To date, there is no consensus in “clinically relevant outcomes” among researchers, pharmaceutical companies, and regulatory authorities. This is the urgent problem to be resolved in this research area.


Further consideration is needed to identify the most suitable study design and endpoints, which can lead to the development of pharmacological and nonpharmacological interventions that improve patients’ prognosis and outcomes.

MD. PhD. Tateaki Naito
Shizuoka Cancer Center

Read the Original

This page is a summary of: Emerging Treatment Options For Cancer-Associated Cachexia: A Literature Review, Therapeutics and Clinical Risk Management, October 2019, Taylor & Francis,
DOI: 10.2147/tcrm.s196802.
You can read the full text:




The following have contributed to this page